Adrenal gland enhancement at MR imaging with Mn-DPDP
Related Experiment Video
Updated: Aug 9, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
D G Mitchell1, E K Outwater, T Matteucci
1Department of Radiology, Thomas Jefferson University Hospital, Philadelphia, PA.
Purpose:
To determine adrenal gland enhancement with manganese (II) N,N' dipyridoxylethylenediamine-N,N'-diacetate 5,5'bis(phosphate) (DPDP) at magnetic resonance imaging.
Materials And Methods:
After phase III trials, fat-suppressed, motion-compensated, T1-weighted spin-echo images (repetition time, 500 msec; echo time, 12 msec) of 13 consecutive patients were obtained at 1.5 T at one site, prior to and approximately 30 minutes after intravenous administration of 5 mumol/kg Mn-DPDP. Images were analyzed visually and by means of region-of-interest measurements, normalized to spleen. With data added from three more sites, enhancement of three adrenal adenomas and two metastases was analyzed.
Results:
Twenty-five of 26 adrenal glands were depicted on MR images, and all showed enhancement. Mean adrenal enhancement (38%) was comparable to mean enhancement of liver (46%), pancreas (25%), and renal cortex (58%). Adrenal cortex and medulla could not be distinguished in nonenhanced or enhanced images. All three adrenal adenomas enhanced by more than 40%, but the metastases did not enhance.
Conclusion:
Functioning adrenal tissue (glands and at least some adenomas) are enhanced with Mn-DPDP.
Insights
Manganese (II) N,N
Area of Science:
- Radiology
- Medical Imaging
- Contrast Agents
Background:
- Adrenal gland imaging is crucial for diagnosing various conditions.
- Enhancement patterns can aid in differentiating adrenal lesions.
- Novel contrast agents are continuously being developed for improved MRI.
Purpose of the Study:
- To evaluate the enhancement characteristics of adrenal glands using manganese (II) N,N' dipyridoxylethylenediamine-N,N'-diacetate 5,5'bis(phosphate) (Mn-DPDP) in MRI.
- To assess Mn-DPDP as a potential contrast agent for adrenal imaging.
Main Methods:
- 13 consecutive patients underwent MRI at 1.5 T before and after intravenous Mn-DPDP administration.
- Fat-suppressed, T1-weighted spin-echo images were acquired.
- Region-of-interest measurements, normalized to spleen, were used for analysis.
Main Results:
- All 26 depicted adrenal glands showed enhancement after Mn-DPDP administration.
- Mean adrenal enhancement (38%) was comparable to other organs like liver and renal cortex.
- Adrenal adenomas enhanced significantly (>40%), while metastases did not.
Conclusions:
- Functioning adrenal tissue, including glands and some adenomas, demonstrates enhancement with Mn-DPDP.
- Mn-DPDP shows potential as an MRI contrast agent for evaluating adrenal tissue.
More Related Videos
Related Concept Videos
Magnetic Resonance Imaging
Radiological Investigation III: Pulmonary Angiogram and PET Scan
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
Imaging Studies I: CT and MRI
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...
Imaging Studies for Cardiovascular System IV: CMRI
Imaging Studies III: Computed Tomography
Imaging Studies IV: Magnetic Resonance Imaging

